United Therapeutics Corporation $UTHR Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 27.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,263 shares of the biotechnology company’s stock after selling 5,692 shares during the quarter. Nisa Investment Advisors LLC’s holdings in United Therapeutics were worth $4,386,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the second quarter worth $29,000. SVB Wealth LLC acquired a new position in United Therapeutics during the first quarter worth $32,000. Geneos Wealth Management Inc. raised its holdings in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Brooklyn Investment Group raised its holdings in United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC purchased a new position in United Therapeutics during the first quarter worth $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $431.50, for a total transaction of $4,746,500.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $15,871,001.50. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $417.50, for a total value of $9,393,750.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 349,435 shares of company stock valued at $144,451,272. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 1.4%

Shares of NASDAQ:UTHR opened at $415.34 on Wednesday. The company has a market cap of $18.74 billion, a P/E ratio of 16.21, a P/E/G ratio of 4.59 and a beta of 0.66. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The business has a fifty day simple moving average of $401.57 and a 200-day simple moving average of $334.83.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm earned $5.85 EPS. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on UTHR shares. Morgan Stanley raised their price target on United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Cantor Fitzgerald raised their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. HC Wainwright raised their price target on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Oppenheimer raised their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, JPMorgan Chase & Co. dropped their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $461.62.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.